1. Summary of the Week

From January 10 to 16, a total of 20 agreements were signed worldwide. Within China’s biotech industry, there were six out-licensing deals and three domestic deals.

The top deal in China was between RemeGen and AbbVie for the Phase II asset PD-1/VEGF bispecific antibody RC148, with an upfront payment of USD 650 million and a total deal value of USD 5.6 billion.

Globally, 11 deals were announced. The top global deal was between Nuvation Bio and Eisai for the approved asset taletrectinib, with an upfront payment of USD 60 million and a total deal value of USD 230 million.

2026年1月10日-16日，全球医药市场共签署了20项资产授权和合作协议。中国市场共达成9项交易，包括6项出海交易，和3项国内交易。

国内市场上，本周最引入注目的交易是荣昌生物与Abbvie就临床二期资产PD-1/VEGF双抗RC148达成独家许可协议，首付款6.5亿美元，总金额可达56亿美元。

国际市场上，本周共签署了11项资产授权和合作协议。最大的一项交易是Nuvation Bio与Eisai就已获批资产taletrectinib在部分国家和地区达成独家许可协议，首付款6000万美元，总金额可达2.3亿美元。

2. Licensing Deals

2a. China Section

2b. Global Section

3. M&A Deals

4. Top Deals of 2025

5. 2019-2024 China Innovative Drug Licensing Transactions

---

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong, proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions.  For more information, please visit http://www.yafocapital.com

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。